TwinBeech Capital’s Janux Therapeutics JANX Stock Holding History

TwinBeech Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-58,810	Closed	-$812K	–	697
2025 Q4	$812K	Buy	+58,810	New	+$1.38M	0.06%	335
2025 Q3	–	Sell	-81,882	Closed	-$1.89M	–	695
2025 Q2	$1.89M	Buy	81,882 +4,445	+6%	+$117K	0.04%	331
2025 Q1	$2.09M	Buy	+77,437	New	+$2.92M	0.04%	386
2024 Q3	–	Sell	-33,516	Closed	-$1.4M	–	776
2024 Q2	$1.4M	Buy	+33,516	New	+$1.57M	0.03%	369

Other funds holding JANX

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

TwinBeech Capital's JANX Position: Q1 2026 in Review

TwinBeech Capital sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 58,810 shares — an estimated $812K sold.

TwinBeech Capital first reported a position in JANX in Q2 2024 and held it in 4 quarters. The position peaked at $2.09M in Q1 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

TwinBeech Capital reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
TwinBeech Capital sold 58,810 Janux Therapeutics shares in Q1 2026, an estimated $812K.
TwinBeech Capital first reported a position in Janux Therapeutics in Q2 2024 and held it in 4 quarters.
TwinBeech Capital's Janux Therapeutics position peaked at $2.09M in Q1 2025.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.